Researchers cite prescriber uncertainty about interpreting pharmacogenetic test results
WOONSOCKET, R.I., Nov. 13, 2013 /PRNewswire/ -- A new study conducted by researchers at CVS Caremark (NYSE: CVS) and Brigham and Women's Hospital explores the impact of genetic testing on prescribing patterns for cardiovascular therapy. The study, published in the November issue of the American Heart Association journal Circulation: Cardiovascular Quality and Outcomes, found that only one in five patients who tested as poor metabolizers of the blood thinner clopidogrel had their antiplatelet therapy changed as recommended by the U. S. Food and Drug Administration (FDA). In addition, the study found that prescribers declined genetic testing in 25 percent of cases evaluated, while less than 10 percent of patients who were directly offered the genetic evaluation declined testing. The researchers concluded that the prescribing patterns noted in the study likely reflect the unclear impact and physician uncertainty regarding the rapidly evolving body of evidence for pharmacogenomics.
"We're entering an age when we can begin to create tailored treatment regimens for individual patients, but a genetic test is only valuable when providers and their patients can understand and act on the results," said Troyen A. Brennan, MD, MPH, executive vice president and chief medical officer of CVS Caremark and a study co-author. "This research shows there is an opportunity to improve upon the information doctors and patients receive on this evolving topic so that they can make the best treatment decisions."
The study examined prescribing patterns for patients with recent acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) who were prescribed the antiplatelet medication clopidogrel. While clopidogrel has been shown to reduce the risk of major adverse cardiovascular events for these patients, there is significant variability in how individual patients respond to the drug. In fact, patients who are poor metabolizers of clopidogrel may have reduced therapeutic benefit and a higher risk of adverse cardiovascular events. The FDA has advised avoiding the use of clopidogrel in patients who are poor metabolizers and recently modified the boxed warning to advise health care professionals to consider the use of other antiplatelet medications or alternative dosing strategies for poor metabolizers.
Health care providers were offered access to a genetic test as part of the patient's health benefit to identify the patient's ability to metabolize clopidogrel. Nearly 500 patients completed the test, with approximately one-third of patients identified as being poor drug metabolizers. While the patients who underwent genetic testing were significantly more likely to have their antiplatelet regimen changed as compared to patients who did not undergo testing, only 20.5 percent of patients identified as being poor metabolizers had their antiplatelet therapy intensified or changed to another drug.
"In this study, about half of the providers that were contacted about the availability of a genetic testing benefit did not respond at all, and among those who did decide to use the test, the vast majority of patients identified as poor metabolizers did not have a change in therapy despite FDA warnings suggesting that they should," said Niteesh K. Choudhry, MD, PhD, associate physician, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, associate professor, Harvard Medical School and the study's senior investigator. "While there is significant uncertainty about how clinician's should respond to the results of genetic testing for antiplatelet drugs, this study clearly shows that patients and their doctors need more guidance and education about how best to apply these results to improve patient outcomes."
About CVS Caremark
CVS Caremark is dedicated to helping people on their path to better health as the largest integrated pharmacy company in the United States. Through the company's more than 7,600 CVS/pharmacy stores; its leading pharmacy benefit manager serving more than 60 million plan members; and its retail health clinic system, the largest in the nation with more than 750 MinuteClinic locations, it is a market leader in mail order, retail and specialty pharmacy, retail clinics, and Medicare Part D Prescription Drug Plans. As a pharmacy innovation company with an unmatched breadth of capabilities, CVS Caremark continually strives to improve health and lower costs by developing new approaches such as its unique Pharmacy Advisor program that helps people with chronic diseases such as diabetes obtain and stay on their medications. Find more information about how CVS Caremark is reinventing pharmacy for better health at info.cvscaremark.com.
SOURCE CVS Caremark
|Two New Clinical Studies Show ICU Medical ChemoClave® System Improves Safety by Reducing Hazardous Drug Exposure and Eliminating Accidental Disconnects ()|
|New Peer-Reviewed Study Shows Mixed Results in ACO Medication Readiness To Achieve Quality, Cost Goals ()|
|CVS Caremark Research Finds Optimal Adherence to Medications Prescribed Post-Heart Attack Reduces Hospital Readmissions (2014/1/13)|
|Study Commissioned by CVS Caremark Highlights Opportunities to Significantly Reduce Spending on Costly Specialty Medications (2014/4/9)|
|CVS Caremark Appoints Dr. William Shrank as Chief Scientific Officer and Chief Medical Officer, Provider Innovation and Analytics (2013/11/12)|
|CVS Caremark Research Finds New, More Accurate Method for Classifying Patient Medication Adherence Behaviors (2013/9/12)|
|CVS Caremark Recognizes the Important Role Pharmacists Play in Improving Health Outcomes for their Patients ()|
|CVS Caremark to Buy Medical Provider Coram (2013/11/27)|
|CVS Caremark to Buy Medical Provider Coram for $2.1 Billion ()|
|New Clinical Studies Show ICU Medical's ChemoLock™ Closed System Transfer Device Prevents Hazardous Drug Surface Contamination and Provides a Completely Dry Disconnect ()|
|CVS Caremark Corp||View cvs Stock Quote|
|CVS Caremark Corp||View cvs Stock Quote|
|America Movil, S.A.B. de C.V. ADR||View amx Stock Quote|
|Minera Frisco, S.A.B. de C.V. ADR||View msnfy Stock Quote|
|Gruma, S.A.B. de C.V. ADR||View gmk Stock Quote|
|Maxcom Telecomunicaciones, S.A.B. de C.V. ADR||View mxt Stock Quote|
|Grupo Herdez, S.A.B. de C.V. ADR||View guzby Stock Quote|
|Organizacion Soriana, S.A.B. de C.V. ADR||View ogzsy Stock Quote|
|Coca-Cola Femsa, S.A.B. de C.V. ADR||View kof Stock Quote|
|Grupo Aeroportuario del Sureste, S.A.B. de C.V. ADR||View asr Stock Quote|
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.